AU2021219097A1 - P2X3 modulators - Google Patents

P2X3 modulators Download PDF

Info

Publication number
AU2021219097A1
AU2021219097A1 AU2021219097A AU2021219097A AU2021219097A1 AU 2021219097 A1 AU2021219097 A1 AU 2021219097A1 AU 2021219097 A AU2021219097 A AU 2021219097A AU 2021219097 A AU2021219097 A AU 2021219097A AU 2021219097 A1 AU2021219097 A1 AU 2021219097A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
formula
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021219097A
Other languages
English (en)
Inventor
Nathalie Chauret
Jeremy Green
Karine Villeneuve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health Cough Inc
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of AU2021219097A1 publication Critical patent/AU2021219097A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Burglar Alarm Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021219097A 2020-02-14 2021-02-12 P2X3 modulators Abandoned AU2021219097A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977008P 2020-02-14 2020-02-14
US62/977,008 2020-02-14
PCT/IB2021/000091 WO2021161105A1 (en) 2020-02-14 2021-02-12 P2x3 modulators

Publications (1)

Publication Number Publication Date
AU2021219097A1 true AU2021219097A1 (en) 2022-09-01

Family

ID=77292083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021219097A Abandoned AU2021219097A1 (en) 2020-02-14 2021-02-12 P2X3 modulators

Country Status (11)

Country Link
US (1) US20230312557A1 (https=)
EP (1) EP4103564A4 (https=)
JP (1) JP2023513373A (https=)
KR (1) KR20220141331A (https=)
CN (2) CN119039290A (https=)
AU (1) AU2021219097A1 (https=)
BR (1) BR112022015858A2 (https=)
CA (1) CA3170664A1 (https=)
IL (1) IL295393A (https=)
MX (1) MX2022009762A (https=)
WO (1) WO2021161105A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228760A1 (en) 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
EP4103572A4 (en) * 2020-02-14 2024-03-06 Bellus Health Cough Inc. MAKING A P2X3 ANTAGONIST
WO2021244634A1 (zh) * 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114805237B (zh) * 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
CN114805340A (zh) * 2021-01-22 2022-07-29 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012011518B8 (pt) * 2009-11-18 2023-01-10 Astrazeneca Ab Compostos, composição farmacêutica, kit e usos de um composto
US9598409B2 (en) * 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CA3115939A1 (en) * 2018-10-10 2020-04-16 Bellus Health Cough Inc. Treatment of pruritus with p2x3 antagonists
WO2020135771A1 (zh) * 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
EP4103564A4 (en) 2024-05-01
CN119039290A (zh) 2024-11-29
EP4103564A1 (en) 2022-12-21
KR20220141331A (ko) 2022-10-19
CA3170664A1 (en) 2021-08-19
JP2023513373A (ja) 2023-03-30
US20230312557A1 (en) 2023-10-05
MX2022009762A (es) 2022-09-09
WO2021161105A1 (en) 2021-08-19
CN115413279A (zh) 2022-11-29
IL295393A (en) 2022-10-01
BR112022015858A2 (pt) 2022-10-25

Similar Documents

Publication Publication Date Title
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
AU2021219097A1 (en) P2X3 modulators
CA2748251C (en) Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
US12209081B2 (en) Heterocycle derivatives for treating TRPM3 mediated disorders
EP3634404B1 (en) Pyrazole magl inhibitors
TW202229285A (zh) Kras g12d抑制劑
EP3377060B1 (en) Pyrazole derivatives, processes for their preparation and uses thereof
TWI791153B (zh) Mdm2抑制劑之製備方法及結晶型
JP2022116233A (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
CA3111649A1 (en) Tricyclic compounds acting on crbn proteins
JPWO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
CA3063993A1 (en) Pyrazole magl inhibitors
JP2016540811A (ja) Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
US20250101011A1 (en) Peptidyl nitrile compound and use thereof
EP2740730A1 (en) Dibenzooxepin derivative
CN116583501A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
WO2017162133A1 (zh) 一种具有突变型idh抑制活性的化合物、其制备方法及用途
JPWO2007032371A1 (ja) 摂食調節剤としてのオキシインドール誘導体
CA3228249A1 (en) Nitrogen-containing tricyclic compound and pharmaceutical use thereof
TW202300485A (zh) Plk4抑制劑及其用途
CN113943296B (zh) 吡咯并嘧啶衍生物及其应用
HK40085749A (en) P2x3 modulators
WO2024194352A1 (en) Deuterated p2x3 modulators
HK1258975B (zh) 用於局部药物递送的非甾体类糖皮质激素受体调节剂

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period